Xuzhen Qin1, Jun Shen2, Erhei Dai3, Haolong Li1, Guodong Tang4, Lixia Zhang5, Xin Hou1, Minya Lu1, Xian Wu1, Simeng Duan1, Jingjia Zhang1, Man-Fung Tsoi6, Ping Jiang3, Yongzhe Li7. 1. Department of Laboratory Medicine, Peking Union Medical College Hospital & Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 2. Department of Administrative Office, Haihe University, Tianjin, China. 3. Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China. 4. Department of Cardiology, Beijing Hospital of the Ministry of Health, Beijing, China. 5. Department of Clinical Laboratory, Haihe University, Tianjin, China. 6. Department of Medicine, University of Hong Kong, Hong Kong, China. 7. Department of Laboratory Medicine, Peking Union Medical College Hospital & Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. yongzhelipumch@126.com.
Abstract
BACKGROUND: SARS-CoV-2 is a novel coronavirus first recognized in late December 2019 that causes coronavirus disease 19 (COVID-19). Due to the highly contagious nature of SARS-CoV-2, it has developed into a global pandemic in just a few months. Antibody testing is an effective method to supplement the diagnosis of COVID-19. However, multicentre studies are lacking to support the understanding of the seroprevalence and kinetics of SARS-CoV-2 antibodies in COVID-19 epidemic regions. METHOD: A multicentre cross-sectional study of suspected and confirmed patients from 4 epidemic cities in China and a cohort study of consecutive follow-up patients were conducted from 29/01/2020 to 12/03/2020. IgM and IgG antibodies elicited by SARS-CoV-2 were tested by a chemiluminescence assay. Clinical information, including basic demographic data, clinical classification, and time interval from onset to sampling, was collected from each centre. RESULTS: A total of 571 patients were enrolled in the cross-sectional study, including 235 COVID-19 patients and 336 suspected patients, each with 91.9%:2.1% seroprevalence of SARS-CoV-2 IgG and 92.3%:5.4% seroprevalence of SARS-CoV-2 IgM. The seroprevalence of SARS-CoV-2 IgM and IgG in COVID-19 patients was over 70% less than 7 days after symptom onset. Thirty COVID-19 patients were enrolled in the cohort study and followed up for 20 days. The peak concentrations of IgM and IgG were reached on the 10th and 20th days, respectively, after symptom onset. The seroprevalence of COVID-19 IgG and IgM increased along with the clinical classification and treatment time delay. CONCLUSION: We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibodies in COVID-19 patients and the association between clinical classification and antibodies, which will contribute to the interpretation of IgM and IgG SARS-CoV-2 antibody tests and in predicting the outcomes of patients with COVID-19.
BACKGROUND:SARS-CoV-2 is a novel coronavirus first recognized in late December 2019 that causes coronavirus disease 19 (COVID-19). Due to the highly contagious nature of SARS-CoV-2, it has developed into a global pandemic in just a few months. Antibody testing is an effective method to supplement the diagnosis of COVID-19. However, multicentre studies are lacking to support the understanding of the seroprevalence and kinetics of SARS-CoV-2 antibodies in COVID-19 epidemic regions. METHOD: A multicentre cross-sectional study of suspected and confirmed patients from 4 epidemic cities in China and a cohort study of consecutive follow-up patients were conducted from 29/01/2020 to 12/03/2020. IgM and IgG antibodies elicited by SARS-CoV-2 were tested by a chemiluminescence assay. Clinical information, including basic demographic data, clinical classification, and time interval from onset to sampling, was collected from each centre. RESULTS: A total of 571 patients were enrolled in the cross-sectional study, including 235 COVID-19patients and 336 suspected patients, each with 91.9%:2.1% seroprevalence of SARS-CoV-2IgG and 92.3%:5.4% seroprevalence of SARS-CoV-2 IgM. The seroprevalence of SARS-CoV-2 IgM and IgG in COVID-19patients was over 70% less than 7 days after symptom onset. Thirty COVID-19patients were enrolled in the cohort study and followed up for 20 days. The peak concentrations of IgM and IgG were reached on the 10th and 20th days, respectively, after symptom onset. The seroprevalence of COVID-19IgG and IgM increased along with the clinical classification and treatment time delay. CONCLUSION: We demonstrated the kinetics of IgM and IgGSARS-CoV-2 antibodies in COVID-19patients and the association between clinical classification and antibodies, which will contribute to the interpretation of IgM and IgGSARS-CoV-2 antibody tests and in predicting the outcomes of patients with COVID-19.
Authors: Jonathan J Deeks; Jacqueline Dinnes; Yemisi Takwoingi; Clare Davenport; René Spijker; Sian Taylor-Phillips; Ada Adriano; Sophie Beese; Janine Dretzke; Lavinia Ferrante di Ruffano; Isobel M Harris; Malcolm J Price; Sabine Dittrich; Devy Emperador; Lotty Hooft; Mariska Mg Leeflang; Ann Van den Bruel Journal: Cochrane Database Syst Rev Date: 2020-06-25
Authors: Maria Del Rocío Thompson-Bonilla; Jorge A León; Martha Beatriz Cárdenas-Turrent; Alba Peña-Thompson; Diana Hanessian-De la Garza; Sergio Zavala-Vega; Juan Xicohtencatl-Cortes; Sara A Ochoa; Ariadnna Cruz-Córdova; José Arellano-Galindo Journal: J Int Med Res Date: 2022-07 Impact factor: 1.573